Raltegravir in treatment nave patients

F. Cossarini, A. Castagna, A. Lazzarin

Research output: Contribution to journalArticle

Abstract

Abstract. Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses. Studies on nave patients showed comparable efficacy of raltegravir and efavirenz and just recently the US Food and Drug Administration (FDA) approved raltegravir for the use in nave patients based on the favorable results of the international double-blind phase III STARTMRK trial. Additional interesting findings were the faster, and not yet explained, decay of HIV-1 RNA and the higher CD4+ cells increase in the raltegravir group as compared to the efavirenz group. Raltegravir is generally well tolerated and adverse events were generally similar in raltegravir and comparator arms throughout all studies. When compared to efavirenz, patients on raltegravir showed less incidence of central nervous system-related adverse events. In studies on experienced patients higher incidence of cancers was found in the raltegravir arm: a relationship with the drug was, however not confirmed in a recent review considering all raltegravir studies. Raltegravir also showed a safe lipid profile expecially in nave patients, finding that renders the drug attractive for patients with other cardiovascular risk factors. All this characteristics in association with its specific mechanism of action, make raltegravir an interesting drug for nave patients and a large use in this type of patients is predictable. Only time and experience, however, will tell us whether raltegravir will maintain its promises in the long run.

Original languageEnglish
Pages (from-to)22-29
Number of pages8
JournalEuropean Journal of Medical Research
Volume14
Issue numberSUPPL.3
DOIs
Publication statusPublished - 2009

Fingerprint

efavirenz
Therapeutics
Raltegravir Potassium
Integrase Inhibitors
Pharmaceutical Preparations
Incidence
United States Food and Drug Administration
HIV Infections
HIV-1
Central Nervous System
RNA
Viruses
Lipids
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Raltegravir in treatment nave patients. / Cossarini, F.; Castagna, A.; Lazzarin, A.

In: European Journal of Medical Research, Vol. 14, No. SUPPL.3, 2009, p. 22-29.

Research output: Contribution to journalArticle

Cossarini, F. ; Castagna, A. ; Lazzarin, A. / Raltegravir in treatment nave patients. In: European Journal of Medical Research. 2009 ; Vol. 14, No. SUPPL.3. pp. 22-29.
@article{abd8018a4d1b49818979eb80d4d1594d,
title = "Raltegravir in treatment nave patients",
abstract = "Abstract. Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses. Studies on nave patients showed comparable efficacy of raltegravir and efavirenz and just recently the US Food and Drug Administration (FDA) approved raltegravir for the use in nave patients based on the favorable results of the international double-blind phase III STARTMRK trial. Additional interesting findings were the faster, and not yet explained, decay of HIV-1 RNA and the higher CD4+ cells increase in the raltegravir group as compared to the efavirenz group. Raltegravir is generally well tolerated and adverse events were generally similar in raltegravir and comparator arms throughout all studies. When compared to efavirenz, patients on raltegravir showed less incidence of central nervous system-related adverse events. In studies on experienced patients higher incidence of cancers was found in the raltegravir arm: a relationship with the drug was, however not confirmed in a recent review considering all raltegravir studies. Raltegravir also showed a safe lipid profile expecially in nave patients, finding that renders the drug attractive for patients with other cardiovascular risk factors. All this characteristics in association with its specific mechanism of action, make raltegravir an interesting drug for nave patients and a large use in this type of patients is predictable. Only time and experience, however, will tell us whether raltegravir will maintain its promises in the long run.",
author = "F. Cossarini and A. Castagna and A. Lazzarin",
year = "2009",
doi = "10.1186/2047-783X-14-S3-22",
language = "English",
volume = "14",
pages = "22--29",
journal = "European Journal of Medical Research",
issn = "0949-2321",
publisher = "BioMed Central",
number = "SUPPL.3",

}

TY - JOUR

T1 - Raltegravir in treatment nave patients

AU - Cossarini, F.

AU - Castagna, A.

AU - Lazzarin, A.

PY - 2009

Y1 - 2009

N2 - Abstract. Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses. Studies on nave patients showed comparable efficacy of raltegravir and efavirenz and just recently the US Food and Drug Administration (FDA) approved raltegravir for the use in nave patients based on the favorable results of the international double-blind phase III STARTMRK trial. Additional interesting findings were the faster, and not yet explained, decay of HIV-1 RNA and the higher CD4+ cells increase in the raltegravir group as compared to the efavirenz group. Raltegravir is generally well tolerated and adverse events were generally similar in raltegravir and comparator arms throughout all studies. When compared to efavirenz, patients on raltegravir showed less incidence of central nervous system-related adverse events. In studies on experienced patients higher incidence of cancers was found in the raltegravir arm: a relationship with the drug was, however not confirmed in a recent review considering all raltegravir studies. Raltegravir also showed a safe lipid profile expecially in nave patients, finding that renders the drug attractive for patients with other cardiovascular risk factors. All this characteristics in association with its specific mechanism of action, make raltegravir an interesting drug for nave patients and a large use in this type of patients is predictable. Only time and experience, however, will tell us whether raltegravir will maintain its promises in the long run.

AB - Abstract. Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses. Studies on nave patients showed comparable efficacy of raltegravir and efavirenz and just recently the US Food and Drug Administration (FDA) approved raltegravir for the use in nave patients based on the favorable results of the international double-blind phase III STARTMRK trial. Additional interesting findings were the faster, and not yet explained, decay of HIV-1 RNA and the higher CD4+ cells increase in the raltegravir group as compared to the efavirenz group. Raltegravir is generally well tolerated and adverse events were generally similar in raltegravir and comparator arms throughout all studies. When compared to efavirenz, patients on raltegravir showed less incidence of central nervous system-related adverse events. In studies on experienced patients higher incidence of cancers was found in the raltegravir arm: a relationship with the drug was, however not confirmed in a recent review considering all raltegravir studies. Raltegravir also showed a safe lipid profile expecially in nave patients, finding that renders the drug attractive for patients with other cardiovascular risk factors. All this characteristics in association with its specific mechanism of action, make raltegravir an interesting drug for nave patients and a large use in this type of patients is predictable. Only time and experience, however, will tell us whether raltegravir will maintain its promises in the long run.

UR - http://www.scopus.com/inward/record.url?scp=77951224397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951224397&partnerID=8YFLogxK

U2 - 10.1186/2047-783X-14-S3-22

DO - 10.1186/2047-783X-14-S3-22

M3 - Article

C2 - 19959413

AN - SCOPUS:77951224397

VL - 14

SP - 22

EP - 29

JO - European Journal of Medical Research

JF - European Journal of Medical Research

SN - 0949-2321

IS - SUPPL.3

ER -